Drug Information

Drug General Information
Drug ID
D0G0BJ
Former ID
DIB008231
Drug Name
VE-821
Synonyms
ATR serine/threonine protein kinase inhibitors (cancer), Oxford University; ATR serine/threonine protein kinase inhibitors (cancer), Vertex Pharmaceuticals
Drug Type
Small molecular drug
Indication Cancer [ICD9: 140-229; ICD10:C00-C96] Investigative [542940]
Company
University of Oxford
Formula
C18H16N4O3S
InChI
InChI=1S/C18H16N4O3S/c1-26(24,25)14-9-7-12(8-10-14)15-11-20-17(19)16(22-15)18(23)21-13-5-3-2-4-6-13/h2-11H,1H3,(H2,19,20)(H,21,23)
InChIKey
DUIHHZKTCSNTGM-UHFFFAOYSA-N
PubChem Compound ID
51000408
PubChem Substance ID
117682505, 117699615, 131276094, 131344669, 141081435, 152258595, 160647430, 161005249, 164210377, 170485686, 174007085, 185998840, 208265501, 223382785, 223705230, 224423355, 225848217, 228590768, 248319018, 249565722, 252110117, 252160546, 252216567, 252444692, 252473810, 252735109
Target and Pathway
Target(s) Serine threonine protein kinase ATR Target Info Inhibitor [532880], [532980]
KEGG Pathway Fanconi anemia pathway
Cell cycle
p53 signaling pathway
HTLV-I infection
PANTHER Pathway p53 pathway
p53 pathway feedback loops 2
Pathway Interaction Database Fanconi anemia pathway
ATR signaling pathway
Signaling events mediated by TCPTP
Circadian rhythm pathway
BARD1 signaling events
p53 pathway
Reactome Meiotic synapsis
Activation of ATR in response to replication stress
Regulation of HSF1-mediated heat shock response
HDR through Single Strand Annealing (SSA)
Processing of DNA double-strand break ends
Presynaptic phase of homologous DNA pairing and strand exchange
G2/M DNA damage checkpoint
WikiPathways DNA Damage Response
Meiotic Synapsis
Prostate Cancer
Integrated Breast Cancer Pathway
Integrated Cancer pathway
Cell Cycle
Cell Cycle Checkpoints
miRNA Regulation of DNA Damage Response
References
Ref 542940(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8042).
Ref 532880Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970. Oncotarget. 2014 Jul 30;5(14):5674-85.
Ref 532980ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses. Cancer Res. 2014 Dec 1;74(23):6968-79.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.